Cilnidipine, an L/N-type calcium channel blocker (CCB), has been reported to have more beneficial effects on proteinuria progression in hypertensive patients than amlodipine, an L-type CCB. The N-type calcium channel blockade that inhibits renal sympathetic nerve activity might reduce glomerular hypertension by facilitating vasodilation of the efferent arterioles. However, the precise mechanism of the renoprotective effect of cilnidipine remains unknown. Because cilnidipine exerted significantly higher antioxidant activity than amlodipine in cultured human mesangial cells, we hypothesized that cilnidipine might exert a renoprotective effect by suppressing oxidative stress. A total of 35 hypertensive patients receiving a renin-angiotensin system inhibitor were randomly assigned to a cilnidipine (n ¼ 18; 10 mg per day cilnidipine titrated to 20 mg per day) or amlodipine (n ¼ 17; 5 mg per day amlodipine titrated to 10 mg per day) group; the target blood pressure (BP) was set at 130/85 mmHg. After 6 months of treatment, systolic and diastolic BPs were significantly reduced in both of the groups, without any significant difference between the groups. The urinary albumin, 8-hydroxy-2 0 -deoxyguanosine (OHdG) and liver-type fatty-acid-binding protein (L-FABP) to creatinine ratios significantly decreased in the cilnidipine group (Po0.05) compared with those in the amlodipine group. The reductions in urinary albumin, 8-OHdG and L-FABP were not correlated with the change in systolic BP. In conclusion, cilnidipine, but not amlodipine, ameliorated urinary albumin excretion and decreased urinary 8-OHdG and L-FABP in the hypertensive patients. Cilnidipine probably exerts a greater renoprotective effect through its antioxidative properties.
INTRODUCTION
Patients with chronic kidney disease (CKD) are at a high risk of cardiovascular disease. 1 Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) are beneficial in suppressing the progression of CKD 2,3 and are generally used as first-line treatments in hypertensive patients with CKD. Calcium channel blockers (CCBs) are known to have potent antihypertensive effects and are considered the main candidates in combination treatment with ACEIs or ARBs in hypertensive patients with CKD.
However, evidence of the renoprotective effect of various types of CCBs is inconsistent. This inconsistency might be due to the different specificity of each CCB for different calcium channels. Although cilnidipine, an L/N-type CCB, could suppress renal injury in hypertensive patients, 4, 5 amlodipine, an L-type CCB, could not. 3, 6 Furthermore, cilnidipine was shown to be more beneficial than amlodipine in combined treatment for hypertensive patients with kidney disease and significant proteinuria who were receiving treatment with a renin-angiotensin system (RAS) inhibitor. 7 The beneficial effect of cilnidipine might be attributable to the inhibition of renal sympathetic nerve activity 8 and reduction of glomerular hypertension (because of the vasodilation of efferent arterioles), which are consequences of the N-type calcium channel blockade. However, the precise mechanism underlying the renoprotective effect of cilnidipine remains unknown. Because cilnidipine, which has marked lipophilicity, 9 showed significantly higher antioxidant activity in cultured human mesangial cells than did amlodipine (15), we hypothesized that cilnidipine might exert its renoprotective effects by suppressing oxidative stress.
Extensive experimental evidence suggests that lipids in the cellular membranes, as well as protein and DNA, are exposed to oxidative damage. In nuclear and mitochondrial DNA,
8-hydroxy-2
0 -deoxyguanosine (OHdG) is one of the predominant sources of free radical-induced oxidative stress. 10 Therefore, 8-OHdG has widely been used as a biomarker of oxidative stress and has been shown to be associated with the progression of CKD. 11, 12 Urinary liver-type fatty-acid-binding protein (L-FABP) is a useful biomarker for renal tubulointerstitial injury and can be used to monitor both hemodynamic and drug responses in animal models and CKD patients. 13, 14 In addition, urinary L-FABP is more sensitive than urinary protein in predicting the progression of CKD. 13 In the present study, the urinary excretion levels of 8-OHdG and L-FABP were used as markers of oxidative stress and tubular injury, respectively. In addition, the antioxidative and antiproteinuric effects of cilnidipine were compared with those of amlodipine in hypertensive patients who were receiving treatment with a RAS inhibitor.
METHODS

Study design
In this 6-month-long, multi-center, prospective, randomized, open-labeled clinical trial named Tokushima Antioxidation Clinical Trial in Hypertensives, Cilnidipine vs. Amlodipine (TACTICAL) study, 35 hypertensive patients receiving RAS treatment (ACEI or ARB) at four hospitals in Japan were included between March 2009 and January 2011. The study was approved by the Institutional Review Board of The University of Tokushima Clinical Research Center and the review board of the four hospitals. The study protocol was in accordance with the Declaration of Helsinki Principles. Written informed consent was obtained from all the patients included in this study. The enrollment criteria were: (1) hypertension defined as systolic and diastolic blood pressure (BP) of X140/90 mmHg, (2) treatment with a RAS inhibitor for 3 months or more before the administration of cilnidipine or amlodipine and (3) serum creatinine level of p2.0 mg dl À1 . The exclusion criteria were as follows: (1) age o45 years or 485 years, (2) hypertensive emergency, (3) severe heart failure, severe arrhythmia, angina, myocardial infarction and stroke within 6 months of the start of the trial, (4) pregnancy and (5) history of severe adverse effects of CCBs and RAS inhibitors.
The overview of the study design is shown in Figure 1 . The subjects were randomly assigned to two groups at the time of registration. The patients received either of the following treatment regimens: 10 mg per day cilnidipine, which was titrated up to daily doses of 20 mg, or 5 mg per day amlodipine, which was titrated up to daily doses of 10 mg, to achieve the BP-target levels.
The doses of ARB and ACEI were not altered during the study period. The target BP level was 130/85 mmHg. BP was measured according to the Japanese Society of Hypertension Guidelines for Measurement of Hypertension. 15 During the first 3 months of the study, the patients were administered the assigned combination drug regimen at baseline. However, if cilnidipine or amlodipine in combination with the RAS inhibitor failed to reduce the BP to the target level within 3 months, additional antihypertensive medications, such as diuretics, were administered to achieve the target BP.
Dyslipidemia was defined according to the criteria established by the Japan Atherosclerosis Society (low-density lipoprotein X140 mg dl À1 , trigylcerides X150 mg dl À1 and/or high-density lipoprotein o40 mg dl À1 ) 16 in addition to a medical history of hypercholesterolemia.
Measurements of urinary parameters
Morning-spot urine samples were obtained. The urinary levels of albumin and creatinine were measured using turbidimetric immunoassay and enzyme assay, respectively (Mitsubishi Chemical Medience, Tokyo, Japan). The urinary levels of 8-OHdG and L-FABP were measured using the sandwich enzyme-linked immunosorbent assay kit (NOF, Tokyo, Japan, and Immuno-Biological Lab, Tokyo, Japan). Urinary albumin, 8-OHdG and L-FABP levels were expressed as the ratio to the urinary creatinine concentration.
Statistical analysis
Data are expressed as the mean±s.d. Differences between the two groups were analyzed by Student's unpaired t-test for continuous variables and Chi-square test for categorical variables. The changes between before and after the administration of the therapy were assessed by Wilcoxon's signed-rank test. Correlations between two parameters were assessed using simple linear regression.
RESULTS
Baseline characteristics
No adverse effects related to the antihypertensive treatment occurred during the study period. The baseline characteristics of the subjects are shown in Table 1 . There were no significant differences in age, gender, systolic and diastolic BPs, body mass index, diabetes mellitus incidence and dyslipidemia between the two groups. There were also no significant differences in the use of ARB/ACEI, beta-blockers and statins between the two groups.
Changes in BP and heart rate Systolic and diastolic BPs were significantly lower in both the cilnidipine and amlodipine groups at 6 months after the antihypertensive therapy compared with baseline values (Po0.01). However, there were no significant differences in the BPs between the two groups ( Figure 2a ). There was no change in the heart rate after 6 months of treatment in either of the groups, although the heart rate tended to be decreased in the cilnidipine group (Figure 2b ).
Changes in urinary albumin
The urinary albumin/creatinine ratio significantly decreased in the cilnidipine group after the 6-month treatment compared with that in the amlodipine group (Po0.05; Figure 3 ).
Changes in urinary 8-OHdG and L-FABP
The urinary 8-OHdG (8-OHdG/creatinine ratio) and L-FABP levels (L-FABP/creatinine ratio) decreased significantly after 6-month cilnidipine treatment, whereas it did not change after amlodipine treatment (Figures 4 and 5, respectively) . In addition, the urinary albumin, 8-OHdG and L-FABP reduction rates were not correlated with the systolic BP change rate ( Figure 6 ). Figure 2 Changes in BP and heart rate during the study period. The BP and heart rate were almost the same between the cilnidipine (closed circles) and amlodipine (open circles) groups. Systolic and diastolic BP values were significantly reduced in both the groups after 6 months of treatment. Heart rate remained unchanged after 6 months of treatment in both the groups. Renoprotective effect of cilnidipine T Soeki et al
DISCUSSION
The results of the present study suggested that cilnidipine had greater antiproteinuric effects than amlodipine when used in combination with a RAS inhibitor to treat hypertensive patients. Furthermore, to our knowledge, this is the first study showing higher antioxidant activity of cilnidipine than amlodipine. Our results are in agreement with those of previous studies, showing that cilnidipine had greater antiproteinuric effects than amlodipine when used in combination therapy. 5, 8 The Cilnidipine vs. Amlodipine Randomized Trial for Evaluation in Renal Disease study showed that cilnidipine was more beneficial than amlodipine in hypertensive patients. 7 Besides RAS inhibition, strict control of BP is considered important for preventing the progression of kidney disease. 15, 17, 18 Both cilnidipine and amlodipine effectively reduced BP level in hypertensive patients after 6 months of treatment. Furthermore, there was no significant correlation between change in BP and change in albuminuria level after a 6-month treatment with cilnidipine. These results suggest that the antiproteinuric effect of cilnidipine might be independent of the effect on BP, which is compatible with the results of the Cilnidipine vs. Amlodipine Randomized Trial for Evaluation in Renal Disease study.
The greater antiproteinuric effect and BP reduction accomplished by cilnidipine than amlodipine might be due to its N-type calciumchannel blockade action. Cilnidipine inhibits norepinephrine secretion 19 and neurally stimulated renal vasoconstriction. 20 Because the sympathetic nerve activity affects both afferent and efferent arterioles, the inhibition of N-type calcium channels would dilate both the types of arterioles. Previous experimental studies have shown that cilnidipine causes substantial vasodilation of efferent and afferent arterioles in the canine kidney 20 and that it reduces glomerular hypertension by causing the vasodilation of efferent arterioles. 21 On the other hand, only L-type CCBs are unable to reduce glomerular hypertension because the efferent arterioles lack L-type calcium channels. 22 Loss of redox homeostasis and formation of excessive free radicals have an important role in the pathogenesis of kidney disease and hypertension. The former contributes to the activation of the proinflammatory and profibrotic pathways in the kidney, leading to reduced vascular compliance and proteinuria. 23 Dihydropyridine derivatives have been shown to act as lipophilic chain-breaking antioxidants. 24 A recent study measured the ionomycin-stimulated superoxide production in cultured human mesangial cells and showed that cilnidipine has stronger antioxidant activity than amlodipine at the clinical plasma concentration. 9 The stronger antioxidant activity of cilnidipine may be attributed to the greater difference in lipophilicity between cilnidipine and amlodipine, as reported by a previous study. 25 Therefore, we hypothesized that cilnidipine might exert the renoprotective effect at least partially by suppressing oxidative stress that causes cellular injury and promotes glomerular and renal tubule injuries.
Another possibility for the cilnidipine-mediated suppression of proteinuria and oxidative stress in hypertensive patients receiving RAS-inhibitor treatment might be the inhibition of the renal RAS system by cilnidipine. Moreover, even previous studies reported better renoprotective effects of cilnidipine than amlodipine. 26, 27 Cilnidipine was shown to prevent the increase in renal angiotensin II content in spontaneously hypertensive rat/ND mcr-cp (an obese spontaneously hypertensive model). 26 In addition, it reduced renal ACE activity and renal aldosterone content in uninephrectomized deoxycorticosterone-salt hypertensive rats. 27 However, in the present study, the activity of renal RAS system in hypertensive patients was not evaluated.
Our study has several limitations. First, we could perform serial measurements of the urinary levels of albumin, 8-OHdG and L-FABP for only a limited number of patients and time points. Second, although we showed the collected data simultaneously for urinary albumin excretion, 8-OHdG and L-FABP, we could not show that antioxidant effects were the direct mechanism by which cilnidpine provided renoprotection in the present study. Renoprotective effect of cilnidipine T Soeki et al
In conclusion, we showed that combination therapy with cilnidipine, and not amlodipine, ameliorated urinary albumin excretion in hypertensive patients receiving RAS-inhibitor treatment. Furthermore, cilnidipine decreased the urinary 8-OHdG and L-FABP levels in these patients. These data suggest that cilnidipine has greater renoprotective and antioxidative effects than amlodipine in hypertensive patients. Further research needs to be conducted to confirm the mechanisms underlying the beneficial effects of cilnidipine in hypertensive patients.
